|
|
|
European Biopharmaceutical Review
|
| The evolving fields of genomics and proteomics are developing into essential tools in the discovery and development of new medicines. A wide variety of techniques have been developed which allow the detection of information ranging from a single nucleotide polymorphism (SNP) to complete expression profiles. Despite these advances there remains an ongoing drive to reduce the cost of research and development in order to minimise the expense of bringing a new drug or diagnostic to market. As such, there is increasing demand for large-scale bioassay analysis using smaller reagent volumes and at a lower cost per test. As a result a variety of 'multiplexing' technologies have emerged over the last few years which allow researchers to perform millions of parallel biological tests on a miniature scale. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Ciaran Sewter and Dr Mark Evans, Development Scientists, and Dr Elizabeth Hill, Chief Executive Officer at 3D Molecular Sciences Ltd
Dr Ciaran Sewter is a Development Scientist at 3D Molecular Sciences Ltd. He has a BSc in Biological Sciences from the University of East Anglia and a PhD from the University of Cambridge.
Dr Sewter has expertise in molecular and cell biology and has held a number of academic and industrial positions in obesity/diabetes research, immunology and virology.
Dr Mark Evans works as a Development Scientist at 3D Molecular Sciences Ltd. Having completed his first degree in Biochemistry at the University of Plymouth, Dr Evans obtained a PhD from the Department of Analytical Chemistry at Loughborough University, based on the development of biospecific assays for drugs of pharmaceutical interest. After two years as a Research Fellow, he became Head of Assay Automation at Kalibrant Ltd, before joining 3D Molecular Sciences in October 2002. His main areas of expertise are fluidics, instrumentation, automation, solid state devices and fluorescence.
Dr Elizabeth Hill is Chief Executive Officer and Co-Founder of 3D Molecular Sciences Ltd. She has 20 years' experience in the biotechnology, life sciences and health care sectors. Dr Hill started her career in instrumentation with Philips Scientific, subsequently moving into biotechnology, where she was a principal participant in the MBO of Enzymatix leading to Chiroscience and Celsis, and the subsequent IPO of the latter. She graduated with a First Class Honours degree in Chemistry and was awarded a PhD at King's College London for developing electrochemiluminescence as a detection technique for HPLC.
|
|
|
|
|
|
 |
Industry Events |
 |
2012 BIO International Convention
18-21 June 2012, Boston, Massachusetts
Connect, partner and innovate at the 2012 BIO International Convention, June 18-21, Boston, Mass. Network with 15,000+ global biotech leaders in the BIO Business Forum, Exhibition and Programme.
More info >> |
|
 |
News and Press Releases |
 |
Pantec Biosolutions Showcases P.L.E.A.S.E.® Professional at the IMCAS Annual Congress
Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will present its recently launched P.L.E.A.S.E.® Professional laser device at the International Master Course on Aging Skin (IMCAS) from 26th-29th January 2012 in Paris, France.
More info >> |
|
|
